STOCK TITAN

ProCap Financial (BRR) registers 51M shares and satisfies Nasdaq board and audit rules

(Neutral)
(Neutral)
Form Type
424B3

Rhea-AI Filing Summary

ProCap Financial, Inc. filed a prospectus supplement updating a prior prospectus for the registration of 51,024,833 shares of Common Stock. This consists of the resale of up to 20,100,833 existing shares by selling securityholders, the resale of up to 18,071,500 shares issuable upon conversion of Convertible Notes, and the issuance of up to 12,852,500 shares upon exercise of Public and Private Warrants. The Common Stock trades on the Nasdaq Global Market under "BRR" and the Warrants on the Nasdaq Capital Market under "BRRWW", with March 3, 2026 closing prices of $2.95 per share and $0.4631 per Warrant, respectively. ProCap is an emerging growth company using reduced reporting requirements.

The company also reported that Nasdaq’s Listing Qualifications staff has determined ProCap now complies with Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b)(1) regarding independent directors and audit committee composition, following the appointment of Benjamin Buchanan to the Board and audit committee, and that this deficiency matter is closed.

Positive

  • None.

Negative

  • None.

Filing Explained

The August 10 supplement keeps 51,024,833 shares registered for resale or potential warrant exercise; it does not report a sale, note conversion, or warrant exercise. Registration alone sells nothing, so the disclosed share count is capacity rather than completed issuance.

Total shares covered 51,024,833 shares of Common Stock Total shares described in the prospectus supplement and Prospectus
Resale shares 20,100,833 shares of Common Stock Existing shares offered for resale by selling securityholders
Shares from Convertible Notes 18,071,500 shares of Common Stock Shares issuable upon conversion of the Convertible Notes for resale
Shares from Warrants 12,852,500 shares of Common Stock Shares issuable upon exercise of 12,852,500 Warrants
Warrant exercise price $11.50 per share Exercise price for each whole redeemable warrant
Common Stock price $2.95 per share BRR closing price on March 3, 2026
Warrant price $0.4631 per Warrant BRRWW closing price on March 3, 2026
prospectus supplement regulatory
"This prospectus supplement updates and supplements the information contained in the prospectus"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Convertible Notes financial
"shares of Common Stock issuable upon conversion of the Convertible Notes"
Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.
Public Warrants financial
"12,852,500 warrants, including 12,500,000 public warrants (the “Public Warrants”)"
Public warrants are tradable securities that give the holder the right to buy a company’s stock at a fixed price before a set expiration date. Like a coupon that lets you purchase shares later at a preset price, they matter to investors because using them can bring new cash into the company but also increase the total number of shares outstanding, which can dilute existing ownership and influence the stock’s price and potential gains.
Private Warrants financial
"352,500 private warrants (the “Private Warrants” and together with the Public Warrants"
A private warrant is a contract sold directly to selected investors that gives the holder the right to buy a company’s stock at a fixed price in the future. Think of it as a coupon for shares that isn’t offered on public markets: it can provide the company with future cash if exercised but can also dilute existing shareholders by increasing the number of outstanding shares, so investors watch exercise price, expiration and transfer restrictions closely.
emerging growth company regulatory
"We are an “emerging growth company” as defined under U.S. federal securities laws"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b)(1) regulatory
"not in compliance with the independent director and audit committee requirements set forth in Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b)(1)"
Offering Type shelf/secondary/supplement

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many shares are covered by ProCap Financial (BRR)'s latest prospectus supplement?

The prospectus supplement covers 51,024,833 shares of Common Stock. This includes existing shares for resale, shares from Convertible Notes, and shares issuable upon exercise of 12,852,500 Warrants.

What are the main components of the 51,024,833 ProCap Financial (BRR) shares registered?

The registration includes 20,100,833 existing shares for resale, up to 18,071,500 shares issuable upon conversion of Convertible Notes, and up to 12,852,500 shares issuable upon exercise of Public and Private Warrants.

On which exchanges do ProCap Financial (BRR) securities trade and at what recent prices?

ProCap’s Common Stock trades on the Nasdaq Global Market under "BRR" and its Warrants on the Nasdaq Capital Market under "BRRWW". On March 3, 2026, BRR closed at $2.95 and BRRWW at $0.4631.

What Nasdaq compliance issue did ProCap Financial (BRR) resolve?

ProCap received confirmation it now complies with Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b)(1) on independent directors and audit committee composition, and Nasdaq staff advised that the listing deficiency matter is closed.

How did ProCap Financial (BRR) regain compliance with Nasdaq board and audit rules?

ProCap regained compliance after appointing Benjamin Buchanan to its Board of Directors and audit committee. Nasdaq staff reviewed this appointment and determined the company now meets the applicable independent director and audit committee requirements.

Is ProCap Financial (BRR) an emerging growth company and what does that imply?

ProCap states it is an emerging growth company under U.S. securities laws. This status allows the company to follow reduced public company reporting requirements compared with larger, more established issuers.

What types of Warrants back ProCap Financial (BRR)'s registered warrant shares?

The 12,852,500 registered warrant shares are tied to 12,500,000 Public Warrants and 352,500 Private Warrants. Each whole warrant is exercisable for one share of Common Stock at an exercise price of $11.50 per share.

 

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-292590

 

PROSPECTUS SUPPLEMENT DATED August 10, 2026

TO THE PROSPECTUS DATED JANUARY 20, 2026

 

20,100,833 Shares of Common Stock

18,071,500 Shares of Common Stock Issuable Upon Conversion of the Convertible Notes

12,852,500 Shares of Common Stock Issuable Upon Exercise of the Warrants

 

ProCap Financial, Inc.

 

This prospectus supplement updates and supplements the information contained in the prospectus dated January 20, 2026 (as may be supplemented or amended from time to time, the “Prospectus”), which forms part of our registration statement on Form S-1 (File No. 333-292590) with the information contained in our Annual Report on Form 10-Q that was filed with the Securities and Exchange Commission on May 14, 2026 (the “Annual Report”). Accordingly, we have attached the Annual Report to this prospectus supplement.

 

The Prospectus and this prospectus supplement relates to 51,024,833 shares of our common stock, par value $0.001 per share (“Common Stock”), which consists of (i) the resale of up to 20,100,833 shares of our Common Stock by certain of the selling securityholders named in this prospectus (each a “Selling Securityholder” and, collectively, the “Selling Securityholders”), (ii) the resale of up to 18,071,500 shares of Common Stock issuable upon conversion of the Convertible Notes (as defined below) by the Selling Securityholders, and (iii) the issuance by the Company of up to 12,852,500 shares of Common Stock that are issuable upon the exercise of 12,852,500 warrants, including 12,500,000 public warrants (the “Public Warrants”) and 352,500 private warrants (the “Private Warrants” and together with the Public Warrants, the “Warrants”).

 

You should read this prospectus supplement in conjunction with the Prospectus. This prospectus supplement is qualified by reference to the Prospectus except to the extent that the information in this prospectus supplement supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. Terms used in this prospectus supplement but not defined herein shall have the meanings given to such terms in the Prospectus.

 

Our Common Stock is listed on the Nasdaq Global Market under the symbol “BRR” and our Warrants are listed on the Nasdaq Capital Market under the symbol “BRRWW.” On March 3, 2026, the closing price of our Common Stock was $2.95 and the closing price for our Warrants was $0.4631.

 

We are an “emerging growth company” as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company.

 

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 6 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of the prospectus. Any representation to the contrary is a criminal offense.

 

The date of this prospectus supplement is August 10, 2026.

 

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 21, 2026

 

PROCAP FINANCIAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-42995   39-2767031
(State or other jurisdiction
of incorporation)
 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

600 Lexington Avenue, Floor 2

New York, New York 10022

(Address of principal executive offices) (Zip Code)

 

(305) 938-0912

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   BRR   The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share   BRRWW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01. Other Events.

 

As previously disclosed, on January 26, 2026, ProCap Financial, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the independent director and audit committee requirements for continued listing on the Nasdaq Global Market set forth in Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b)(1), respectively (the “Rules”), as disclosed in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 23, 2026.

 

On July 16, 2026, the Company filed a Current Report on Form 8-K with the SEC disclosing the appointment of Benjamin Buchanan to the Company’s Board of Directors and its audit committee.

 

On July 21, 2026, the Company received a letter from the Staff advising that, based on the information regarding the appointment of Mr. Buchanan to the Company’s Board of Directors and audit committee as detailed in the Company’s Current Report on Form 8-K filed July 16, 2026, the Staff has determined that the Company complies with the Rules and that the matter is now closed.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description of Exhibit
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  PROCAP FINANCIAL, INC.
     
Date: July 21, 2026 By: /s/ Anthony Pompliano
  Name: Anthony Pompliano
  Title: Chief Executive Officer